secwatch.observer — SEC 8-K summary
======================================

Issuer:     MIRA PHARMACEUTICALS, INC. (MIRA)
CIK:        0001904286
Form:       8-K
Filed at:   2025-10-15T23:59:59+00:00
Accession:  0001493152-25-018141
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

MIRA Pharmaceuticals: Oral Mira-55 normalized pain, reduced inflammation, outperforming injected morphine
--------------------------------------------------------------------------------

- Oral Mira-55 normalized pain thresholds to baseline and reduced paw edema in formalin-induced chronic pain model, outperforming injected morphine.
- Mira-55 showed direct CB2-receptor-mediated anti-inflammatory effect; morphine only partial indirect effect.
- First study to directly measure inflammation alongside pain; supports planned IND for chronic inflammatory pain.
- Company targeting $70 billion non-opioid pain market with dual-mechanism drug addressing both cause and perception of pain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1904286/000149315225018141/0001493152-25-018141-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1904286/000149315225018141/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-018141

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer